Optimization of the small-scale synthesis of DOTA-Tyr-octreotide

Nuclear Medicine Communications

Volumn 23, Issue 5, 2002, Pages 493-499

  Edreira, M ^a   Melendez Alafort, L ^a   Mather, S J ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

DOTA; In 111; Y 90

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; OCTREOTIDE; PENTETREOTIDE; RADIOPHARMACEUTICAL AGENT;

ANALYTIC METHOD; ARTICLE; BINDING AFFINITY; DRUG SYNTHESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; NUCLEAR MEDICINE; PEPTIDE SYNTHESIS; PROTEIN PURIFICATION; REACTION OPTIMIZATION; RECEPTOR BINDING; SOLID PHASE EXTRACTION; TISSUE DISTRIBUTION;

ANIMALS; HETEROCYCLIC COMPOUNDS, 1-RING; INDIUM RADIOISOTOPES; MODELS, CHEMICAL; MODELS, MOLECULAR; MOLECULAR WEIGHT; OCTREOTIDE; RATS; RECEPTORS, SOMATOSTATIN;

EID: 0036256211     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/00006231-200205000-00010     Document Type: Article

References (22)

1. Reubi J, Laissue J, Krenning E, Lamberts S. Somatostatin receptors in human cancer: characteristics, functional correlates and clinical implications. J Steroid Biochem Mol Biol 1992; 43: 27-35.
2. Kwekkeboom D, Krenning E, De Jong M. Peptide receptor imaging and therapy. J Nucl Med 2000; 41: 1704-1713.
3. 123I-Tyr]octreotide: The Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993; 20: 716-731.
4. Krenning E, Bakker W, Kooij P, et al. Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide. J Nucl Med 1992; 33: 652-658.
5. Krenning EP, Kooij PP, Bakker WH, et al. Radiotherapy with a radiolabeled somatostatin analogue, [111In-DTPA-D-Phe1]-octreotide. A case history. Ann NY Acad Sci 1994; 733: 496-506.
6. Krenning E, Kooij P, Pauwels S, et al. Somatostatin receptor: scintigraphy and radionuclide therapy. Digestion 1996; 57(Suppl.): 57-61.
7. Otte A, Jermann E, Behe M, et al. DOTATOC: a powerful new tool for receptor-mediated radionuclide therapy. Eur J Nucl Med 1997; 24: 792-795.
8. 3] octreotide as carriers for somatostatin receptor-targeted scintigraphy and radionuclide therapy. Int J Cancer 1998; 75: 406-411.
9. Froidevaux S, Heppeler A, Eberle A, et al. Preclinical Comparison in AR4-2J tumor-bearing mice of four radiolabeled 1,4,7,10-tetraazacyclodecane-1,4,7,10-tetraacetic acid-somatostatin analogs for tumor diagnosis and internal radiotherapy. Endocrinology 2000; 141: 3304-3312.
10. Heppeler A, Froidevaux S, Mäcke H, et al. Radiometal-labelled macrocyclic chelator-derivatised somatostatin analogue with superb tumour-targeting properties and potential for receptor-mediated internal radiotherapy. Chem Eur J 1999; 5: 1974-1981.
11. 3] octreotide. Bioconjugate Chem 1999; 10: 431-438.
12. 3]octreotide, a promising somatostatin analogue for radionuclide therapy. Eur J Nucl Med 1997; 24: 368-371.
13. 90Y-SMT 487) eradicates experimental rat pancreatic CA 20948 tumours. Eur J Nucl Med 1998; 25: 668-674
14. Otte A, Herrmann R, Heppler A, et al. Yttrium-90 DOTATOC: first clinical results. Eur J Nucl Med 1999; 26: 1439-1447.
15. 90Y-DOTOTOC. Eur J Nucl Med 1999; 26: 877-886.
16. Smith-Jones PM, Bischof C, Leimer M, et al. DOTA-lanreotide: a novel somatostatin analog for tumor diagnosis and therapy. Endocrinology 1999; 140: 5136-5148.
17. De Jong M, Bakker WH, Bernard BF, et al. Preclinical and initial clinical evaluation of 111In-labeled nonsulfated CCK8 analog: a peptide for CCK-B receptor-targeted scintigraphy and radionuclide therapy. J Nucl Med 1999; 40: 2081-2087.
18. Van Hagen PM, Breeman WA, Bernard HF, et al. Evaluation of a radiolabelled cyclic DTPA-RGD analogue for tumour imaging and radionuclide therapy. Int J Cancer 2000; 90: 186-198.
19. Liu S, Cheung E, Ziegler MC, Rajopadhye M, Edwards DS. (90)Y and (177)Lu labeling of a DOTA-conjugated vitronectin receptor antagonist useful for tumor therapy. Bioconjug Chem 2001; 12: 559-568.
20. Bussolati G, Chinol M, Chini B, Nacca A, Cassoni P, Paganelli G. 111In-labeled 1,4,7,10-tetraazacyclododecane-N, N′, N′′, N′′′-tetraacetic acid-lys(8)-vasotocin: a new powerful radioligand for oxytocin receptor-expressing tumors. Cancer Res 2001; 61: 4393-4397.
21. Lewis MR, Raubitschek A, Shively JE. A facile, water-soluble method for modification of proteins with DOTA. Use of elevated temperature and optimized pH to achieve high specific activity and high chelate stability in radiolabeled immunoconjugates. Bioconjug Chem 1994; 5: 565-576.
22. Peterson JJ, Pak RH, Meares CF. Total solid-phase synthesis of 1,4,7,10-tetraazacyclododecane-N, N′, N′′, N′′′-tetraacetic acid-functionalized peptides for radioimmunotherapy. Bioconjug Chem 1999; 10: 316-320.